Bartosz Rasiński

Bartosz Rasiński

Auto-generated profile, based on publicly available information

Bartosz Rasiński

Waters Sp. z o.o., Wybrzeże Gdyńskie 6B, 01-531, Warszawa, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2026 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
PMPaulina Markowska
Paulina Markowska
BRBartosz Rasiński
Bartosz Rasiński
HZHubert Ziółkowski
Hubert Ziółkowski
Isoxazoline derivatives have rapidly become cornerstone ectoparasiticides in veterinary medicine, providing high efficacy and long-lasting protection against fleas, ticks, and other arthropods in companion animals and, more recently, in food-producing species. This review summarizes current knowledge on the chemistry, pharmacology, and toxicology of the main veterinary isoxazolines - fluralaner, afoxolaner, sarolaner, and lotilaner - with particular emphasis on safety profiles and broader One Health considerations. Chemically, these compounds are highly lipophilic, fluorinated molecules with distinctive stereochemistry; the selective use of biologically active S-enantiomers has improved potency while limiting off-target effects. Isoxazolines act through non-competitive antagonism of γ-aminobutyric acid (GABA) - and L-glutamate-gated chloride channels in arthropods, resulting in sustained neuronal hyperexcitation and parasite death, with markedly higher affinity for arthropod than mammalian receptors. Pharmacokinetically, the compounds exhibit variable oral bioavailability but share extensive plasma protein binding, large volumes of distribution, low clearance, and long elimination half-lives, which underlie their prolonged clinical efficacy but also raise concerns regarding tissue accumulation and delayed adverse effects. Controlled studies generally demonstrate wide safety margins; however, post-marketing pharmacovigilance has identified rare but sometimes serious neurological adverse events, particularly in predisposed animals or in the context of impaired efflux transport, such as ABCB1/MDR1 mutations or P-glycoprotein inhibition. The authorization of fluralaner for use in laying hens and evidence of residues in eggs approaching established maximum residue limits emphasize the importance of continued residue monitoring and refinement of withdrawal periods. Moreover, the environmental persistence of isoxazolines and their pronounced toxicity to non-target invertebrates highlight emerging ecotoxicological concerns. Collectively, veterinary isoxazolines represent a highly effective yet complex class of antiparasitic agents whose safe and sustainable use requires integrated pharmacological, toxicological, residue, and environmental risk assessment.

1 September 2025 in Journal of Veterinary Research
Verified
Journal Article
Open access
PDF file
PMPaulina Markowska
Paulina Markowska
JJJerzy Jan Jaroszewski
Jerzy Jan Jaroszewski
BRBartosz Rasiński
Bartosz Rasiński
HZHubert Ziółkowski
Hubert Ziółkowski
Introduction: Isoxazoline derivatives such as fluralaner, sarolaner, lotilaner, and afoxolaner are a new class of insecticide and acaricide compounds. These compounds are characterised by rapid action and high efficacy over a period of up to several weeks. A method for identifying all four isoxazoline derivatives in animal and human plasma has not been proposed to date. Therefore, the aim of this study was to develop and validate a novel analytical method for the determination of fluralaner, sarolaner, lotilaner, and afoxolaner in laying hen plasma and to revalidate the proposed method in human, canine and feline plasma. Material and Methods: The plasma concentrations of isoxazoline derivatives were determined by ultra-high performance liquid chromatography–tandem mass spectrometry. Analytical samples were prepared by precipitating proteins with a mixture of 96% acetonitrile and 4% ammonium hydroxide (v/v). Chromatographic separation was achieved on a chromatographic column (1.8 μm 2.1 × 100 mm) using 0.1% formic acid in water and 0.1% formic acid in acetonitrile with gradient elution. Results: The results indicate that the described method is replicable, linear (r 2 = 0.99), precise (1.66% to 14.97%), accurate (1.19% to 11.67%), selective and sensitive (limit of quantitation = 1 ng/mL). Depending on the studied compound and animal species, total recovery reached 85–99%, and the matrix effect did not exceed 15% in any of the analyses. Conclusion: The proposed method is simple, effective, inexpensive and rapid because it requires only a single-step sample preparation protocol.